HTB
-
Featured
HTB September/October 2023
1 September 2023. Related: Editorial.
-
Featured
HTB May/June 2023: HIV and implementation science
1 June 2023. Related: Editorial.
-
Featured
HTB April 2023 (6 April 2023)
6 April 2023. Related: Editorial.
-
Featured
HTB March 2023 (10 March 2023)
10 March 2023. Related: Editorial.
-
Featured
HTB January/February 2023 (1 February 2023)
1 February 2023. Related: Editorial.
-
Featured
In memory: Timothy Ray Brown – the Berlin patient, the first person to be cured of HIV
14 October 2020. Related: In memory.
-
HTB October/November 2023
1 October 2023. Related: Editorial.
-
12th IAS Conference on HIV Science (IAS 2023): further reports
1 October 2023. Related: Conference reports, Conference index, IAS 2023 Brisbane.
-
Uganda report: LGBT+ assaults and human rights violations increase
1 October 2023. Related: Editorial, Special reports, Treatment advocacy, Other news.
-
IAS 2023: Lenacapavir studies at IAS: weekly oral dosing and baseline sensitivity in non-clade B settings
1 October 2023. Related: Conference reports, Antiretrovirals, IAS 2023 Brisbane.
-
IAS 2023: LA-CAB/RPV as first-line ART and implementation studies
1 October 2023. Related: Conference reports, Antiretrovirals.
-
IAS 2023: bNAbs for prevention and cure: antiviral and vaccine-like responses
1 October 2023. Related: Conference reports, Antiretrovirals, HIV prevention and transmission, Cure research, Vaccines and microbicides, IAS 2023 Brisbane.
-
IAS 2023: High rates of re-suppression with dolutegravir in the ADVANCE study
1 October 2023. Related: Conference reports, Treatment strategies, Drug resistance, IAS 2023 Brisbane.
-
IAS 2023: Bictegravir use in pregnancy: more data needed
1 October 2023. Related: Conference reports, Pregnancy.
-
IAS 2023: In-utero tenofovir-based PrEP has no effect on children’s bone mineral density
1 October 2023. Related: Conference reports, Pregnancy, Paediatric care, HIV prevention and transmission, IAS 2023 Brisbane.
-
UK surveys on access to New-Fill for facial lipoatrophy
1 October 2023. Related: Side effects, Lipodystrophy and metabolic complications.
-
>10% weight gain during first two years of ART linked to double the risk of cardiometabolic disease
1 October 2023. Related: Side effects, Lipodystrophy and metabolic complications.
-
EU approves cabotegravir as injectable PrEP
1 October 2023. Related: HIV prevention and transmission.
-
Altered kidney function associated with alcohol and cannabis use by women living with HIV
1 October 2023. Related: Side effects.
-
Early phase 1 HIV vaccine study launched in the US and South Africa
1 October 2023. Related: Vaccines and microbicides.
-
Mutations associated with resistance to dapivirine vaginal ring: reported in 7/38 women seroconverting in the open-label HOPE study
1 October 2023. Related: HIV prevention and transmission.
-
Future meetings and webinars 2023/24
1 October 2023. Related: Future meetings.
-
HTB: no. 10/11 (Oct/Nov 2023) PDF download
1 October 2023. Related: PDFs.
-
Defective HIV proviral particles linked to persistent inflammation and immune activation despite effective ART
1 September 2023. Related: Pathogenesis, Basic science and immunology.
-
HTB: no. 9 (Sept 2023) PDF download
1 September 2023. Related: PDFs.
-
12th IAS Conference on HIV Science (IAS 2023): further reports
1 September 2023. Related: Conference reports, IAS 2023 Brisbane.
-
Non-technical summary of articles in HTB September/October 2023
1 September 2023. Related: Editorial.
-
IAS 2023: Update to navigating the programme and online access
1 September 2023. Related: Conference reports, IAS 2023 Brisbane.
-
IAS 2023: Metabolic and weight changes using GLP-1 agonists in people living with HIV: need for more data
1 September 2023. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications, IAS 2023 Brisbane.
-
IAS 2023: CHAPAS-4 supports better second-line options for children
1 September 2023. Related: Conference reports, Paediatric care.
-
IAS 2023: Rapporteur summary track A – basic science
1 September 2023. Related: Conference reports, Cure research, Basic science and immunology, Vaccines and microbicides, IAS 2023 Brisbane.
-
IAS 2023: Rapporteur summary track C – prevention
1 September 2023. Related: Conference reports, HIV prevention and transmission, IAS 2023 Brisbane.
-
IAS 2023: Rapporteur summary track D – social and behavioural science
1 September 2023. Related: Conference reports, Treatment strategies, IAS 2023 Brisbane.
-
Timing of ART with cryptococcus: Europe and the US cohort data challenged by African RCT data and editorial comment
1 September 2023. Related: Coinfections and complications.
-
Cannabis does not reduce T cells in people living with HIV
1 September 2023. Related: Pathogenesis, Basic science and immunology.
-
Peripheral inflammation linked to structural brain changes and reduced blood flow despite suppressive ART
1 September 2023. Related: Coinfections and complications.
-
Tecovirimat resistance in a person with advanced HIV and delayed ART
1 September 2023. Related: mpox (monkeypox).
-
Breakthrough HIV infection on PrEP with injectable cabotegravir
6 August 2023. Related: HIV prevention and transmission, CROI 30 (Retrovirus) 2023.
-
HTB July/August 2023
1 August 2023. Related: Editorial.
-
Non technical HTB: 11 stories from July/August
1 August 2023. Related: Editorial.
-
12th IAS Conference on HIV Science (IAS 2023)
1 August 2023. Related: Conference reports, IAS 2023 Brisbane.
-
IAS 2023: Update to navigate the programme and online access
1 August 2023. Related: Conference reports, IAS 2023 Brisbane.
-
WHO endorses “zero” transmission risk for people with HIV with an undetectable viral load
1 August 2023. Related: Conference reports, Treatment strategies, HIV prevention and transmission, IAS 2023 Brisbane.
-
Viral load level when suppressed <1000 predicts future rebound: 3-monthly monitoring required
1 August 2023. Related: Conference reports, HIV prevention and transmission, IAS 2023 Brisbane.
-
ART-associated hypertension can be successfully treated in African settings
1 August 2023. Related: Conference reports, Side effects, Coinfections and complications, IAS 2023 Brisbane.
-
REPRIEVE study: statin benefits people living with HIV at low to moderate CVD risk
1 August 2023. Related: Conference reports, Coinfections and complications, IAS 2023 Brisbane.
-
Geneva patient and other HIV cure research at IAS 2023
1 August 2023. Related: Conference reports, Cure research, IAS 2023 Brisbane.
-
Guide to other HIV cure-related research at IAS 2023
1 August 2023. Related: Conference reports, IAS 2023 Brisbane.
-
Rapporteur summaries: track B clinical science
1 August 2023. Related: Conference reports, Antiretrovirals, IAS 2023 Brisbane.
-
Early press conference: cure, gay circumcision, PrEP choices, mpox, and COVID-19
1 August 2023. Related: Conference reports, mpox (monkeypox), HIV prevention and transmission, Cure research, COVID-19: HIV and COVID-19 coinfection, COVID-19, IAS 2023 Brisbane.
-
High rates of occult HBV in Botswana: risks from relying on HBsAg screening
1 August 2023. Related: Conference reports, Hepatitis coinfection, IAS 2023 Brisbane.
-
Anal cancer: 1 in 5 risk of missing precancerous lesions if only HSIL are biopsied
1 August 2023. Related: Conference reports, Cancer and HIV, IAS 2023 Brisbane.
-
BHIVA Annual Conference 2023 (BHIVA 2023) – final reports
1 August 2023. Related: Conference reports, Conference index, BHIVA Gateshead 2023.
-
No vertical HIV transmissions in the UK from women eligible for supported breastfeeding
1 August 2023. Related: Conference reports, Pregnancy, Paediatric care, BHIVA Gateshead 2023.
-
Adverse birth outcomes with diabetes and hypertensive disorders in pregnancy
1 August 2023. Related: Conference reports, Pregnancy, BHIVA Gateshead 2023.